Variable* | All respondents n (%) |
Cannabis users n (%) |
Ondansetron users n (%) |
Users of any prescription antiemetic n (%) |
---|---|---|---|---|
* Sum of nʼs within treatment categories may exceed n of total respondents because treatment categories are not mutually exclusive. † European Union, New Zealand, Norway, South Africa, Africa, Asia, Bermuda, Israel, Kosovo, Kuwait, Malaysia, Mexico, and Turkey (< 5% for each location included in “Other”) ‡ American Indian/Alaska Native, Native Hawaiian or other Pacific Islander, other, prefer not to answer | ||||
Total (n)* | 550 | 76 | 104 | 527 |
Country/continent residence during pregnancy | ||||
|
376 (68.4) 51 (9.3) 35 (6.4) 35 (6.4) 53 (9.5) |
64 (84.2) 7 (9.2) 1 (1.3) 2 (2.6) 2 (2.6) |
73 (70.2) 9 (8.7) 8 (7.7) 9 (8.7) 5 (4.8) |
361 (68.5) 47 (8.9) 34 (6.5) 35 (6.6) 50 (9.5) |
Self-identified ethnicity | ||||
|
433 (79) 37 (7) 24 (4) 21 (4) 35 (6) |
51 (67.1) 10 (13.2) 8 (10.5) 1 (1.3) 6 (3.9) |
89 (85.5) 5 (4.8) 2 (1.9) 1 (1.0) 7 (6.7) |
420 (79.7) 35 (6.6) 21 (4.0) 20 (3.8) 31 (5.9) |
Type of community of residence during most recent pregnancy | ||||
|
305 (56) 104 (25) 138 (19) 2 (< 1) |
38 (50.0) 17 (22.4) 21 (27.6) 0 (0.0) |
60 (57.7) 23 (22.1) 21 (20.2) 0 (0.0) |
296 (56.2) 132 (25.0) 98 (18.6) 1 (0.2) |
Pregnancy status when survey was taken | ||||
|
280 (50.9) 270 (49.1) |
42 (55.3) 34 (44.7) |
69 (66.3) 35 (33.7) |
269 (51.0) 258 (49.0) |
Weeks pregnant at birth during most recent completed pregnancy (if applicable) | ||||
|
226 (83.7) 35 (13.0) 9 (3.3) |
29 (85.3) 5 (14.7) 0 (0.0) |
30 (85.7) 3 (8.6) 2 (5.7) |
214 (82.9) 35 (13.6) 9 (3.5) |
Age during most recent pregnancy | ||||
|
30.2 ± 4.6 | 28.6 ± 5.1 | 29.7 ± 4.1 | 30.2 ± 4.6 |
Experienced weight loss during most recent pregnancy | ||||
|
464 (86.9) 70 (13.1) |
71 (93.4) 5 (6.6) |
88 (86.3) 14 (13.7) |
445 (86.9) 67 (13.1) |